Remove Bioassay Remove Drugs Remove Genomics
article thumbnail

Using analytics and bioassays to de-risk your mRNA LNP drug development programme

Pharmaceutical Technology

“At the small scale, manufacturing between 1 ml and 10 ml is typically not problematic , but it’s not straightforward to replicate processes and technologies once you want to produce tens of litres of formulations,” says Dr Crowe, who manages a team that develop novel analytical assays related to LNPs and nanomaterials for drug delivery.

Bioassay 130
article thumbnail

Evaluating methods targeting Protein-Protein Interactions

pharmaphorum

Understanding the mechanism of PPIs and developing methods to target aberrant ones has been a key strategy in drug development. In comparison with the classic, small molecule drug discovery approach, the modulation of PPIs is more challenging. This innovative method now brings technology closer to developing genome-wide PPI networks.

Protein 126